Buehner, BJ, Morcillo-Nieto, AO, Zsadanyi, SE, Aranha, MR, Arriola-Infante, JE, Vaqué-Alcazar, L, Arranz, J, Rodríguez-Baz, I, Blesa, LM, Videla, L, Barroeta, I, Soriano, LD, Benejam, B, Fernández, S, Hernandez, AS, Bargalló, N, González-Ortiz, S, Giménez, S, de Flores, R, Yushkevich, PA, Alcolea, D, Belbin, O, Lleó, A, Carmona-Iragui, M, Fortea, J, Bejanin, A. Medial temporal lobe atrophy in Down syndrome along the Alzheimer's disease continuum. BRAIN. 2025; 148(7)DOI:10.1093/brain/awaf133. PMID:40243675. IF:11.700(Q1/1D).

Mumford, P, Farrell, C, Kammuri, F, Cannavo, C, Banks, G, Yaman, U, Yu, LJL, Stewart, M, Iulita, MF, Wells, S, Salih, D, Belbin, O, Carmona-Iragui, M, Fortea, J, Wiseman, F. DOWN SYNDROME RESULTS IN AN AMPLIFIED INTERFERON RESPONSE TO AMYLOID-ß THAT IS ASSOCIATED WITH PRODROMAL ALZHEIMER'S DISEASE. GLIA. 2025; 73DOI:. PMID:. IF:5.100(Q1/2D).

González, AC, Goossens, J, Campuzano, EV, Sala, I, Sánchez-Saudinós, MB, Rodríguez-Baz, I, Lidón, L, Perlaza, D, Bejanin, A, Haapasalo, A, Fortea, J, Alcolea, D, Lleo, A, Vanmechelen, E, Belbin, O. Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer's pathophysiological biomarkers. Alzheimers Research & Therapy. 2025; 17(1)DOI:10.1186/s13195-025-01685-y. PMID:39994784. IF:7.600(Q1/1D).

Zsadanyi, SE, Morcillo-Nieto, AO, Aranha, MR, Aragón, I, Arriola-Infante, JE, Vaqué-Alcázar, L, Montal, V, Pegueroles, J, Arranz, J, Rodríguez-Baz, I, Blesa, LM, Videla, L, Barroeta, I, Soriano, LD, Benejam, B, Fernández, S, Hernandez, AS, Bargallo, N, González-Ortiz, S, Giménez, S, Alcolea, D, Belbin, O, Lleó, A, Fortea, J, Carmona-Iragui, M, Bejanin, A. Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome. NEUROLOGY. 2024; 103(4)DOI:10.1212/WNL.0000000000209676. PMID:39074338. IF:8.500(Q1/1D).